Table 2.
Cognitive decline-death intervals and allelic APOE frequencies in TBI+ vs. TBI– subjects.
| All Conditions (MCI+AD+Impaired) | MCI | Dementia | Impaired | |||||
|---|---|---|---|---|---|---|---|---|
| TBI– | TBI+ | TBI– | TBI+ | TBI– | TBI+ | TBI– | TBI+ | |
| Mean cognitive decline-death interval (years) | 5.94 | 3.63* | 6.26 | 4.40* | 5.58 | 3.36* | 6.38 | 4.33 |
| APOE2 allelic frequency (%) | 5.0 | 6.2 | 5.0 | 7.6 | 4.0 | 5.1 | 8 | 5.4 |
| APOE3 allelic frequency (%) | 75.3 | 70.7 | 81.0 | 72.1 | 66.6 | 65.4 | 74 | 78.1 |
| APOE4 allelic frequency (%) | 19.6 | 23.1 | 13.8 | 20.1 | 29.3 | 29.4 | 16 | 16.3 |
The table shows the mean intervals of time between the first cognitive decline assessment and death for all TBI+ and TBI– subjects across all cognitive conditions (MCI, AD, Impaired) at that timepoint as either cumulatively (MCI+AD+Impaired) or separately (MCI, AD, Impaired) considered.
*
Indicates the presence of statistical significance (p < 0.05) for the mean intervals of time (in years) between the first cognitive decline assessment and death for MCI and AD subjects with (TBI+) and without (TBI–) history of traumatic brain injury (TBI) before that first cognitive assessment.